glp 1 drugs and crohn's disease The Potential for GLP-1s in the Treatment of Weight Loss Medications & IBD

[11] Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors

321 , F50F68 (2021)

Beyond its role in glucose regulation, GLP-1 has gained recognition as a therapeutic target in metabolic disorders

Berry-Bibee EN, Kim MJ, Simmons KB, Tepper NK, Riley HE, Pagano HP, et al

The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital

Differential effects of GLP-1RAs on the risk of diverse tumor types Currently, several GLP-1RAs have been approved for the treatment of type 2 diabetes (T2DM) and/or obesity, and emerging evidence suggests that these agents may influence cancer risk